Rating Change
Leerink Partners reiterated its Market Perform rating on Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) on October 07, 2026.
reiterateNASDAQ:RCKT
Leerink Partners Reiterates Market Perform Rating on Rocket Pharmaceuticals, Inc. (RCKT)
Leerink Partners reiterated its Market Perform rating on Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) on October 07, 2026.
At publication ·
What changed
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) · reiterate
- Firm
- Leerink Partners
- Rating
- Market Perform to Market Perform
- Price at event
- $2.54
- Market capitalization
- $372.8M
At a glance
Key takeaways
- Leerink Partners reiterated a Market Perform rating on Rocket Pharmaceuticals (RCKT) on October 7, 2026.
Market Context
Rocket Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $2.54 with a market capitalization of $372.8M.
Analyst coverage from Leerink Partners provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Rocket Pharmaceuticals, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Rocket Pharmaceuticals, Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 07, 2026 | Leerink Partners | Market Perform | N/A |
| Oct 07, 2026 | Wedbush | Outperform | N/A |
| Oct 07, 2026 | Chardan Capital | Buy | N/A |
| Sep 16, 2026 | Needham | Buy | N/A |
| Sep 16, 2026 | Wedbush | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View RCKT Stock Page
Frequently Asked Questions
What does the Market Perform rating mean for RCKT?
A rating of Market Perform from Leerink Partners reflects the analyst's outlook on Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the RCKT forecast page.